MedDataX Logo

Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty

NCT00719056 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 616

Last updated 2008-07-21

No results posted yet for this study

Summary

This is a prospective, open-label, randomized clinical trial where patients were administered prophylaxis for total hip or knee arthroplasty either with teicoplanin or with other antibiotics. The study is aiming to evaluate any differences between these two different strategies of antimicrobial prophylaxis in the occurrence of surgical site infections

Conditions

  • Total Hip and Knee Arthroplasties

Interventions

DRUG

Teicoplanin

The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume

DRUG

β-lactams or ciprofloxacin

Multiple doses for up to six consecutive days

Sponsors & Collaborators

  • KAT Hospital of Athens

    collaborator UNKNOWN

  • University of Athens

    lead OTHER

Principal Investigators

  • Helen Giamarellou, MD, PhD · 4th Department of Internal Medicine, University of Athens, Medical School, Greece

  • Amyntas Varvaroussis, MD · 3rd Department of Orthopedics, KAT Hospital, Maroussi, Greece

  • Panagiotis Papadelis, MD · 2nd Department of Orthopedics, KAT Hospital, Maroussi, Greece

  • Vassilios Nikolaidis, MD · 4th Department of Orthopedics, KAT Hospital, Maroussi, Greece

  • Antonios Papadopoulos, MD, PhD · 4th Department of Internal Medicine, University of Athens, Medical School, Greece

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-12-31
Completion
2007-12-31

Countries

  • Greece

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719056 on ClinicalTrials.gov